HUP0500439A2 - Propofol vízoldható előgyógyszerét tartalmazó vizes alapú gyógyászati készítmények - Google Patents

Propofol vízoldható előgyógyszerét tartalmazó vizes alapú gyógyászati készítmények

Info

Publication number
HUP0500439A2
HUP0500439A2 HU0500439A HUP0500439A HUP0500439A2 HU P0500439 A2 HUP0500439 A2 HU P0500439A2 HU 0500439 A HU0500439 A HU 0500439A HU P0500439 A HUP0500439 A HU P0500439A HU P0500439 A2 HUP0500439 A2 HU P0500439A2
Authority
HU
Hungary
Prior art keywords
propofol
water
pharmaceutical formulations
aqueous based
based pharmaceutical
Prior art date
Application number
HU0500439A
Other languages
English (en)
Inventor
Tracey L. Rogers
Jeffrey A. Williamson
Christopher A. Rhodes
Original Assignee
Guilford Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharmaceuticals, Inc. filed Critical Guilford Pharmaceuticals, Inc.
Publication of HUP0500439A2 publication Critical patent/HUP0500439A2/hu
Publication of HU229293B1 publication Critical patent/HU229293B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgyát gyógyászati készítmény képezi, amely vizesoldatban (i) terápiásan hatásos mennyiségben (I) általános képletűvegyületet, ahol a képletben mindegyik Z jelentése egymástólfiiggetlenül hidrogénatom, alkálifémion és amincsoport közülválasztott; és (ii) hatásos mennyiségben antioxidánst tartalmaz. Atalálmány szerinti gyógyászati készítmény előnyösen antioxidánst,izotóniát beállító szert és pufferanyagot is tartalmazhat. A találmányszerinti (I) általános képletű vegyületként előnyösen O-foszfonooximetil-propofolt tartalmaz, ami anesztetikumként nyeralkalmazást.
HU0500439A 2001-12-28 2002-12-26 Propofol vízoldható elõgyógyszerét tartalmazó vizes alapú gyógyászati készítmények HU229293B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34275501P 2001-12-28 2001-12-28
PCT/US2002/041468 WO2003057153A2 (en) 2001-12-28 2002-12-26 Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol

Publications (2)

Publication Number Publication Date
HUP0500439A2 true HUP0500439A2 (hu) 2005-08-29
HU229293B1 HU229293B1 (hu) 2013-10-28

Family

ID=23343142

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500439A HU229293B1 (hu) 2001-12-28 2002-12-26 Propofol vízoldható elõgyógyszerét tartalmazó vizes alapú gyógyászati készítmények

Country Status (22)

Country Link
US (1) US20050042280A1 (hu)
EP (1) EP1458355B1 (hu)
JP (2) JP2005517679A (hu)
KR (2) KR20040080444A (hu)
CN (1) CN1329036C (hu)
AT (1) ATE430571T1 (hu)
AU (1) AU2002364238B2 (hu)
BR (1) BR0215303A (hu)
CA (1) CA2470500C (hu)
DE (1) DE60232271D1 (hu)
ES (1) ES2325918T3 (hu)
HK (1) HK1069976A1 (hu)
HU (1) HU229293B1 (hu)
IL (3) IL162692A0 (hu)
MX (1) MXPA04006325A (hu)
NO (1) NO334424B1 (hu)
NZ (1) NZ533536A (hu)
PL (1) PL205271B1 (hu)
RU (1) RU2316317C2 (hu)
UA (1) UA76802C2 (hu)
WO (1) WO2003057153A2 (hu)
ZA (1) ZA200404616B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004286814A1 (en) 2003-10-24 2005-05-19 Auspex Pharmaceuticals, Inc. pH sensitive prodrugs of 2,6-diisopropylphenol
US7589239B2 (en) 2005-09-02 2009-09-15 Auspex Pharmaceuticals Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
EP2068630A4 (en) * 2006-10-05 2010-12-29 Eisai Inc AQUEOUS PHARMACEUTICAL FORMULATIONS OF WATER SOLUBLE PRODRUGS OF PROPOFOL
EP2152651B1 (en) 2007-05-09 2012-01-04 Pharmacofore, Inc. Therapeutic compounds
WO2008141097A2 (en) 2007-05-09 2008-11-20 Pharmacofore, Inc. Stereoisomers propofol therapeutic compounds
US20090098209A1 (en) * 2007-10-15 2009-04-16 University Of Kansas Pharmaceutical compositions containing water-soluble derivatives of propofol and methods of administering same via pulmonary administration
GB0905834D0 (en) 2009-04-03 2009-05-20 Seps Pharma Nv Phosphonyl-containing phenolic derivatives useful as medicaments
UY34072A (es) 2011-05-17 2013-01-03 Novartis Ag Derivados sustituidos de indol
CN110063947A (zh) * 2018-01-24 2019-07-30 四川海思科制药有限公司 苯酚衍生物用于制备***物中的用途
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
JP2022108079A (ja) * 2021-01-12 2022-07-25 日本光電工業株式会社 生体情報処理装置、生体情報処理方法、プログラム及び記憶媒体
CN114129578A (zh) * 2021-09-28 2022-03-04 瑞普（天津）生物药业有限公司 甲磷丙泊酚钠在制备宠物麻醉、镇静药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2829151A (en) * 1952-11-03 1958-04-01 Dow Chemical Co Chlorotoloxy-ethyl phosphates
US3271314A (en) * 1958-12-04 1966-09-06 Ethyl Corp 2, 6-diisopropylphenol
GB1146173A (en) * 1966-06-18 1969-03-19 Geigy Uk Ltd Production of triaryl phosphates
US3723578A (en) * 1970-10-13 1973-03-27 Gaf Corp Phosphate esters of ethers of thiol substituted phenols
US4171272A (en) * 1977-12-02 1979-10-16 Fmc Corporation Turbine lubricant
FR2601259B1 (fr) * 1986-07-11 1990-06-22 Rhone Poulenc Chimie Nouvelles compositions tensio-actives a base d'esters phosphoriques leur procede de preparation et leur application a la formulation de matieres actives.
MY103951A (en) * 1988-01-12 1993-10-30 Kao Corp Detergent composition
US5091211A (en) * 1989-08-17 1992-02-25 Lord Corporation Coating method utilizing phosphoric acid esters
US5110503A (en) * 1990-05-15 1992-05-05 Elliot Cohen Demulsifying
JP2869186B2 (ja) * 1990-10-17 1999-03-10 株式会社トーメン 植物における生物活性剤の吸収移行を促進する方法及び組成物
NZ258610A (en) * 1992-12-11 1997-05-26 Smithkline Beecham Plc Various 4-acylamino-2h-benzo[b]pyran-3-ol derivatives;use in preparation of medicaments
US5646176A (en) * 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
KR960008645B1 (ko) * 1993-09-08 1996-06-28 동국제약 주식회사 오르토-이소프로필화 페놀 유도체의 제조방법
US5731355A (en) * 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
IT1270093B (it) * 1994-09-28 1997-04-28 Zambon Spa Processo per la purificazione di 2,6-diisopropilfenolo
US5804682A (en) * 1995-11-29 1998-09-08 Henkel Corporation Aqueous dispersions of polyamides
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
US5723538A (en) * 1996-06-14 1998-03-03 Henkel Corporation Aqueous dispersions of polyamides
US5746973A (en) * 1996-07-10 1998-05-05 Naraghi; Ali Method for reducing odorant depletion
US6254853B1 (en) * 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
EA004708B1 (ru) * 2000-02-04 2004-06-24 Эли Лилли Энд Компани Фармацевтическая композиция, включающая пеметрексед вместе с монотиоглицерином, l-цистеином или тиогликолевой кислотой
MXPA02011531A (es) * 2000-05-25 2003-04-25 Astrazeneca Ab Beneficio de superviviencia.
IN187686B (hu) * 2000-06-21 2002-06-08 Bharat Serums & Vaccines Ltd
US6362234B1 (en) * 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin

Also Published As

Publication number Publication date
EP1458355B1 (en) 2009-05-06
MXPA04006325A (es) 2005-03-31
IL208697A0 (en) 2010-12-30
JP2010235622A (ja) 2010-10-21
RU2004119056A (ru) 2005-04-20
ATE430571T1 (de) 2009-05-15
ES2325918T3 (es) 2009-09-24
ZA200404616B (en) 2005-10-26
WO2003057153A3 (en) 2004-01-29
NO20042459L (no) 2004-08-25
KR20040080444A (ko) 2004-09-18
WO2003057153A2 (en) 2003-07-17
CA2470500A1 (en) 2003-07-17
AU2002364238B2 (en) 2007-01-18
JP2005517679A (ja) 2005-06-16
NO334424B1 (no) 2014-03-03
KR20100112632A (ko) 2010-10-19
PL205271B1 (pl) 2010-03-31
IL162692A (en) 2011-03-31
HK1069976A1 (en) 2005-06-10
CA2470500C (en) 2012-05-15
US20050042280A1 (en) 2005-02-24
DE60232271D1 (de) 2009-06-18
AU2002364238A1 (en) 2003-07-24
HU229293B1 (hu) 2013-10-28
RU2316317C2 (ru) 2008-02-10
NZ533536A (en) 2006-11-30
CN1329036C (zh) 2007-08-01
PL372324A1 (en) 2005-07-11
IL162692A0 (en) 2005-11-20
EP1458355A4 (en) 2005-04-20
BR0215303A (pt) 2005-04-05
UA76802C2 (uk) 2006-09-15
EP1458355A2 (en) 2004-09-22
CN1607938A (zh) 2005-04-20

Similar Documents

Publication Publication Date Title
HUP0500439A2 (hu) Propofol vízoldható előgyógyszerét tartalmazó vizes alapú gyógyászati készítmények
BR0210507A (pt) Azaindóis
HK1076605A1 (en) Formulations
SE0103836D0 (sv) Novel compounds
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
SE0102438D0 (sv) New compounds
EE05103B1 (et) Famatseutilised kompositsioonid, mis sisaldavad asetidiini derivaate, asetidiini derivaadid ja nende valmistamise meetodid
HK1084941A1 (en) Compounds and their use
SE0302760D0 (sv) New compounds
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
MEP10408A (en) Platinum derivative pharmaceutical formulations
ATE332301T1 (de) Antivirale pyrazolopyridin verbindungen
IS2750B (is) Leiðarafesting
YU7804A (sh) Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
BR0212069A (pt) Agentes antidiabéticos orais
MXPA05011176A (es) Derivados de carboxamida como agentes antidiabeticos.
SE0102440D0 (sv) New compound
SE0101038D0 (sv) Novel compounds
DE60233552D1 (de) Fenofibrattabletten
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral
DE60201074D1 (en) Pyrazolopyridinderivate
DK1105379T3 (da) Vandopløselige analoger og medikamentforstadier til paclitaxel
BR0206841A (pt) Modificação cristalina de um depsipeptìdeo cìclico com melhor eficácia
IT1307786B1 (it) Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: MGI GP, INC., US

Free format text: FORMER OWNER(S): GUILFORD PHARMACEUTICALS, INC., US

GB9A Succession in title

Owner name: EISAI CORPORATION OF NORTH AMERICA, US

Free format text: FORMER OWNER(S): GUILFORD PHARMACEUTICALS, INC., US; MGI GP, INC., US

GB9A Succession in title

Owner name: EISAI INC., US

Free format text: FORMER OWNER(S): GUILFORD PHARMACEUTICALS, INC., US; EISAI CORPORATION OF NORTH AMERICA, US; MGI GP, INC., US

MM4A Lapse of definitive patent protection due to non-payment of fees